Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics Limited has announced the issuance of 5,435,254 unquoted securities, set to expire on March 31, 2026, with an exercise price of $0.004. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX, potentially impacting the company’s financial structure and stakeholder interests.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative therapies. The company is primarily engaged in the research and development of cell therapies for cancer treatment, aiming to provide advanced solutions in the field of oncology.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.75M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.